Rua Life Sciences PLC
LSE:RUA

Watchlist Manager
Rua Life Sciences PLC Logo
Rua Life Sciences PLC
LSE:RUA
Watchlist
Price: 17.75 GBX -2.74% Market Closed
Market Cap: £11m

P/OCF

-57.1
Current
465%
More Expensive
vs 3-y average of -10.1

Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.

P/OCF
-57.1
=
Market Cap
GBX7.9m
/
Operating Cash Flow
£-193k

Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.

P/OCF
-57.1
=
Market Cap
GBX7.9m
/
Operating Cash Flow
£-193k

Valuation Scenarios

Rua Life Sciences PLC is trading above its industry average

If P/OCF returns to its Industry Average (0.1), the stock would be worth GBX-0.04 (100% downside from current price).

Statistics
Positive Scenarios
0/2
Maximum Downside
-100%
Maximum Upside
No Upside Scenarios
Average Downside
100%
Scenario P/OCF Value Implied Price Upside/Downside
Current Multiple -57.1 GBX17.75
0%
Industry Average 0.1 GBX-0.04
-100%
Country Average 0.1 GBX-0.03
-100%

Forward P/OCF
Today’s price vs future operating cash flow

Not enough data available to calculate forward P/OCF

Peer Comparison

All Multiples
P/OCF
P/E
All Countries
Close
Market Cap P/OCF P/E
UK
Rua Life Sciences PLC
LSE:RUA
11m GBP -57.1 -50.5
US
Medline Inc
NASDAQ:MDLN
58.8B USD 0 0
JP
Hoya Corp
TSE:7741
9.7T JPY 38.4 38.6
CH
Alcon AG
SIX:ALC
29.2B CHF 16.1 37.3
DK
Coloplast A/S
CSE:COLO B
94.7B DKK 13.7 23.5
US
Align Technology Inc
NASDAQ:ALGN
13.5B USD 22.8 33
UK
ConvaTec Group PLC
LSE:CTEC
4.3B GBP 12.2 32.7
CA
Bausch + Lomb Corp
NYSE:BLCO
5.6B USD 19.7 -15.5
JP
Asahi Intecc Co Ltd
TSE:7747
890.2B JPY 22 50.3
CN
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
36.7B CNY 26.3 23.3
KR
HLB Inc
KOSDAQ:028300
8T KRW -86.1 -36.2
P/E Multiple
Earnings Growth PEG
UK
Rua Life Sciences PLC
LSE:RUA
Average P/E: 34.1
Negative Multiple: -50.5
N/A N/A
US
M
Medline Inc
NASDAQ:MDLN
Not Available
30%
N/A
JP
Hoya Corp
TSE:7741
38.6
15%
2.6
CH
Alcon AG
SIX:ALC
37.3
32%
1.2
DK
Coloplast A/S
CSE:COLO B
23.5
21%
1.1
US
Align Technology Inc
NASDAQ:ALGN
33
34%
1
UK
ConvaTec Group PLC
LSE:CTEC
32.7
41%
0.8
CA
Bausch + Lomb Corp
NYSE:BLCO
Negative Multiple: -15.5 N/A N/A
JP
A
Asahi Intecc Co Ltd
TSE:7747
50.3
40%
1.3
CN
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
23.3
9%
2.6
KR
H
HLB Inc
KOSDAQ:028300
Negative Multiple: -36.2 N/A N/A

Market Distribution

Lower than 100% of companies in United Kingdom
Percentile
0th
Based on 2 384 companies
0th percentile
-57.1
Low
0 — 0.1
Typical Range
0.1 — 0.2
High
0.2 —
Distribution Statistics
United Kingdom
Min 0
30th Percentile 0.1
Median 0.1
70th Percentile 0.2
Max 2 143.8

Rua Life Sciences PLC
Glance View

Market Cap
11m GBX
Industry
Health Care

RUA Life Sciences Plc is a holding company, which engages in the commercialization of biomedical polymer technology, components, and medical devices. The company is headquartered in Ayrshire, Ayrshire and currently employs 32 full-time employees. The firm is a manufacturer of medical devices and licensor of its IP and know-how together with developing medical devices utilizing its polymer IP. The firm operates through four businesses. Its RUA Medical business provides sub-contract manufacturing, assembly, packing and services to the medical device sector from its Class seven and eight cleanroom suites. Its RUA Biomaterials is the depository of the IP and licensing rights to a range of biostable, implantable polymers, including Elast-EonTM and ECSilTM. Its RUA Vascular business is the legal manufacturer and IP holder of the Company’s cardiovascular and soft tissue patches and bore vascular grafts. Its RUA Structural Heart business holds the intellectual property relating to the Company’s synthetic heart valve technology.

RUA Intrinsic Value
12.24 GBX
Overvaluation 31%
Intrinsic Value
Price GBX17.75
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett